IP Library Granted Patent US 12,097,246
Granted Patent B2
US 12,097,246 · App. 17/846,130 · Granted Sep 24, 2024

Methods of treating spinal cord injury

Inventors: Vinod Labhasetwar (Cleveland, OH); Hayder H. Jaffer (Cleveland, OH)
Assignee: The Cleveland Clinic Foundation
A61K38/446A61K9/0019A61K9/19A61K9/5153A61K38/44C12Y111/01006C12Y115/01001
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,097,246
App. No.
17/846,130
Granted
Sep 24, 2024
Kind
B2
Abstract

The invention is directed to a method of treating a spinal cord injury, a neurodegenerative disease or a neuronal injury in an individual in need thereof comprising administering an effective amount of superoxide dismutase (SOD) and catalase to the individual, wherein the superoxide dismutase and the catalase are encapsulated in one or more nanoparticles that release the SOD and catalase upon administration. Another aspect of the invention is directed to compositions comprising superoxide dismutase (SOD) and catalase encapsulated in one or more nanoparticles.

Claims (27)

1. A method of treating a spinal cord in an individual prior to, during, and/or following a medical intervention comprising:

administering intravenously an effective amount of superoxide dismutase (SOD) and catalase to the individual before, during, and/or after a medical intervention that treats one or more of the following: a herniated disc, a spinal fusion, spinal stenosis, a spinal cord injury where scar tissue has been removed, or need for spinal decompression,

wherein the SOD and the catalase are encapsulated in one or more nanoparticles that localize at the spinal cord and release the SOD and the catalase,

wherein the nanoparticles comprise poly (D,L-lactide co-glycolide) (PLGA) and polyvinyl alcohol;

wherein said individual has one or more of the following: a herniated disc, a spinal fusion, spinal stenosis, a spinal cord injury where scar tissue has been removed, or need for spinal decompression.

2. The method of claim 1 , wherein the SOD and the catalase are encapsulated in separate nanoparticles.

3. The method of claim 1 , wherein each of the one or more nanoparticles comprise the SOD and the catalase.

4. The method of claim 1 , wherein the one or more nanoparticles further comprise L-tartaric acid dimethyl ester.

5. The method of claim 1 , wherein the SOD and the catalase are administered simultaneously to the individual.

6. The method of claim 1 , wherein first the catalase is administered to the individual, then the SOD is administered to the individual.

7. The method of claim 1 , wherein the one or more nanoparticles are biodegradable.

8. The method of claim 1 , wherein said individual has a herniated disc.

9. The method of claim 1 , wherein said individual has a spinal fusion.

10. The method of claim 1 , wherein said individual has spinal stenosis.

11. The method of claim 1 , wherein said individual has a need for spinal decompression.

12. The method of claim 1 , wherein said individual has a spinal cord injury where scar tissue has been removed.

13. The method of claim 1 , further comprising administering one or more cells, growth factors, tissue grafts, antioxidants, hormones, steroids, vitamins, minerals or a combination thereof.

14. The method of claim 1 , wherein the one or more nanoparticles are formulated as a lyophilized powder and are reconstituted prior to said administering.

15. The method of claim 1 , wherein the individual is a human, wherein said SOD is human SOD, and wherein said catalase is human catalase.

16. The method of claim 1 , wherein said one or more nanoparticles are present in a composition, and wherein said composition further comprises a pharmaceutically acceptable carrier.

17. The method of claim 16 , wherein said pharmaceutically acceptable carrier comprises a carbohydrate.

18. The method of claim 17 , wherein said carbohydrate comprises lactose.

19. The method of claim 1 , wherein said one or more nanoparticles have a diameter of 100 to 300 nanometers.

20. The method of claim 1 , wherein after administration, some of the SOD and some of the catalase is released rapidly from the one or more nanoparticles, and then the SOD and the catalase that remains in the one or more nanoparticles is released slowly over a sustained period of time.

21. The method of claim 1 , wherein said administering is following said medical intervention.

22. The method of claim 1 , wherein said administering is prior to said medical intervention.

23. The method of claim 1 , wherein said administering is during said medical intervention.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jan 31, 2024
From: CLEVELAND CLINIC FOUNDATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 066383/0123 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2022
From: LABHASETWAR, VINOD D; JAFFER, HAYDER H
To: THE CLEVELAND CLINIC FOUNDATION
Reel/Frame 060516/0284 →
Continuity (3)
Continuation 14766449
Provisional Application 61762008 · Feb 7, 2013
Related Publication 20220313794A1 · Oct 6, 2022